Belimumab shows promise in neuropsychiatric lupus: Another challenge to find the offender
Abstract Introduction Agents that can be used for the treatment of neuropsychiatric lupus (NPSLE) are lacking in the therapeutic armamentarium. Belimumab is a monoclonal antibody targeting the B‐cell activating factor (BAFF) and is approved by the US Food and Drug Administration as an additional tre...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-06-01
|
| Series: | Rheumatology & Autoimmunity |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/rai2.12071 |